WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |
PATENTSCOPE

Search International and National Patent Collections
World Intellectual Property Organization
Search
 
Browse
 
Translate
 
Options
 
News
 
Login
 
Help
 
Machine translation
1. (WO2018005695) USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2018/005695    International Application No.:    PCT/US2017/039829
Publication Date: 04.01.2018 International Filing Date: 28.06.2017
IPC:
A61K 31/4035 (2006.01), A61K 45/06 (2006.01), A61P 17/04 (2006.01)
Applicants: MENLO THERAPEUTICS INC. [US/US]; 4085 Campbell Avenue, Suite 200 Menlo Park, CA 94025 (US)
Inventors: BASTA, Steven; (US).
JOING, Mark; (US).
ZHANG, Xiaoming; (US).
KWON, Paul; (US)
Agent: SILVERMAN, Lisa, N.; (US)
Priority Data:
62/356,280 29.06.2016 US
62/356,291 29.06.2016 US
62/356,301 29.06.2016 US
62/356,294 29.06.2016 US
62/356,286 29.06.2016 US
62/356,271 29.06.2016 US
62/356,264 29.06.2016 US
Title (EN) USE OF NEUROKININ-1 ANTAGONISTS TO TREAT A VARIETY OF PRURITIC CONDITIONS
(FR) UTILISATION D’ANTAGONISTES DE NEUROKININE-1 DANS LE TRAITEMENT D’UNE VARIÉTÉ D’ÉTATS PRURITIQUES
Abstract: front page image
(EN)The disclosure relates to the use of neurokinin-1 (NK-1) antagonists, such as serlopitant, in treating acute or chronic pruritus associated with a variety of medical conditions, including dermatitis/eczema, psoriasis, prurigo, urticaria, cutaneous T-cell lymphoma, epidermolysis bullosa, bums and hepato-biliary diseases, or/and treating the medical conditions themselves. One or more additional antipruritic or therapeutic agents can optionally be used in combination with an NK-1 antagonist to treat acute or chronic pruritus associated with a medical condition or/and the medical condition itself.
(FR)La présente invention concerne l'utilisation d'antagonistes de neurokinine-1 (NK-1), tels que le serlopitant, dans le traitement du prurit aigu ou chronique associé à une variété d'états pathologiques, y compris dermatite/eczéma, psoriasis, prurit, urticaire, lymphome cutané à cellules T, épidermolyse bulleuse, brûlures et maladies hépatobiliaires, et/ou le traitement des états pathologiques eux-mêmes. Un ou plusieurs agents supplémentaires antiprurigineux ou thérapeutiques peuvent facultativement être utilisés en combinaison avec un antagoniste de NK-1 pour traiter un prurit aigu ou chronique associé à un état pathologique et/ou l'état pathologique lui-même.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: English (EN)
Filing Language: English (EN)